Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference

2023 Portfolio Receipts expected to be approximately $3,050 million, exceeding the upper end of guidance rangeAnnounced transactions of $13 billion since 2020 expected to add approximately $1.2...

Related Keywords

United States ,Roche Evrysdi ,Pablo Legorreta ,Johnson Imbruvica ,Novarti Promacta ,Johnson Tremfya ,Nasdaq ,Exchange Commission ,Portfolio Receipts ,Royalty Pharma ,Chief Executive Officer ,Healthcare Conference ,Adjusted Cash ,Royalty Receipts ,Capital Deployment Added Innovative Therapies ,Enhancing Long Term ,Pharma Investor Relations ,Markets ,